

Lhak-Sam, which translates to altruism, embodies the principle of selflessly considering others before oneself. Established in 2010, Lhak-Sam is the sole Bhutan Network of People Living with HIV and AIDS (BNP+) registered under the Civil Society Organization Authority (CSOA) of Bhutan. Observed first-ever International Hepatitis B Day by the government in 2016. This event raised awareness about Hepatitis B testing and treatment, significantly contributing to public health. Additionally, in 2019, the policy on the triple elimination of mother-to-child transmission of HIV, Hepatitis B, and Syphilis was instituted and validated, enabling easier access to services for these three diseases simultaneously.
Following this, public were educated and informed via awareness campaign in the 20 districts about Hepatitis B and C; modes of transmission, preventive measures and treatment. During the National HIV Commission, Lhaksam actively advocated for the inclusion of Hepatitis B and C as national health priorities, recognising their growing threat and co-infection risks among people living with HIV. Despite these efforts, the inclusion of hepatitis in Bhutan’s public health agenda has remained limited, primarily due to the lack of dedicated funding from external donors. This funding gap has resulted in the continued marginalisation of Hepatitis B and C, hindering early detection, treatment, and prevention efforts. As a result, hepatitis remains an overlooked epidemic, posing a significant but under-addressed public health threat in Bhutan.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close